Cerebral vasodilator
(Redirected from Draft:Cerebral vasodilator)
| Cerebral vasodilator | |
|---|---|
| Drug class | |
| Class identifiers | |
| Use | To treat cerebrovascular insufficiency |
| Mode of action | Increase blood flow to the brain |
| Legal status | |
A cerebral vasodilator is a drug which acts as a vasodilator in the brain.[1][2] They are used to improve blood flow in people with cerebrovascular insufficiency and to treat neurological disorders secondary to this condition.[2] A number of different cerebral vasodilators exist.[2][1][3] An example is ifenprodil, which has been marketed for use as a cerebral vasodilator in France, Hong Kong, and Japan.[4][5][6] Other examples include buphenine (nylidrin), isoxsuprine, oxyfedrine, suloctidil, and tinofedrine.[7]
Similar drugs include cerebral activators, or cerebral metabolism activators, like bifemelane, indeloxazine, and teniloxazine, which are also used to treat cerebrovascular disease.[8][9][10][11]
See also
[edit]References
[edit]- ^ a b Toda N, Okamura T (April 1998). "Cerebral vasodilators". Jpn J Pharmacol. 76 (4): 349–367. doi:10.1254/jjp.76.349. PMID 9623714.
- ^ a b c Cook P, James I (December 1981). "Drug therapy: cerebral vasodilators (first of two parts)". N Engl J Med. 305 (25): 1508–1513. doi:10.1056/NEJM198112173052505. PMID 7029283.
- ^ Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA (February 1979). "Vasodilators in senile dementias: a review of the literature". Arch Gen Psychiatry. 36 (2): 220–223. doi:10.1001/archpsyc.1979.01780020110012. PMID 420543.
- ^ Egunlusi AO, Joubert J (May 2024). "NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders". Pharmaceuticals (Basel). 17 (5): 639. doi:10.3390/ph17050639. PMC 11124131. PMID 38794209.
- ^ Tadano T, Yonezawa A, Oyama K, Kisara K, Arai Y, Togashi M, Kinemuchi H (1995). "Effects of transient global ischemia and a monoamine oxidase inhibitor ifenprodil on rat brain monoamine metabolism". Prog Brain Res. 106: 173–80. doi:10.1016/s0079-6123(08)61213-3. PMID 8584652.
- ^ Schweizerischer Apotheker-Verein (2004). Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 625. ISBN 978-3-88763-101-7. Retrieved 2 September 2024.
- ^ Braestrup, C. (2012). Psychotropic Agents: Part II: Anxiolytics, Gerontopsychopharmacological Agents, and Psychomotor Stimulants. Handbook of Experimental Pharmacology. Springer Berlin Heidelberg. pp. 419–420. ISBN 978-3-642-67767-0. Retrieved 17 October 2024.
- ^ Fisman M (1981). "Clinical pharmacology of senile dementia". Prog Neuropsychopharmacol. 5 (5–6): 447–457. doi:10.1016/0364-7722(81)90026-6. PMID 6122228.
- ^ Yamamoto, M; Kawabata, S; Shimizu, M (1989). "Pharmacological effects of indeloxazine, a new cerebral activator, on brain functions distinct from other cerebral metabolic enhancers". Neuropharmacology. 28 (12): 1291–1297. doi:10.1016/0028-3908(89)90001-4. ISSN 0028-3908. PMID 2615913. S2CID 10028363.
- ^ Takahashi, Koichiro; Yamamoto, Minoru; Suzuki, Masanori; Ozawa, Yukiko; Yamaguchi, Takashi; Andoh, Hirofumi; Ishikawa, Kouichi (1995). "Effects of cerebral metabolic enhancers on brain function in rodents". Current Therapeutic Research. 56 (5): 478–485. doi:10.1016/0011-393X(95)85080-5. ISSN 0011-393X.
- ^ van Reekum R, Black SE, Conn D, Clarke D (1997). "Cognition-enhancing drugs in dementia: a guide to the near future". Can J Psychiatry. 42 (Suppl 1): 35S–50S. PMID 9220128.